Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
(Adnkronos) – PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ — EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations.
